Chemomab Therapeutics (CMMB) Projected to Post Quarterly Earnings on Monday

Chemomab Therapeutics (NASDAQ:CMMB) is anticipated to announce its Q4 2025 results before the market opens on Monday, March 2nd. Analysts expect the company to announce earnings of ($0.20) per share for the quarter. Individuals can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Friday, March 6, 2026 at 7:00 AM ET.

Chemomab Therapeutics Stock Up 20.0%

Shares of Chemomab Therapeutics stock opened at $1.86 on Friday. Chemomab Therapeutics has a twelve month low of $1.35 and a twelve month high of $7.04. The business has a 50-day moving average price of $1.67 and a 200-day moving average price of $2.47. The firm has a market cap of $11.46 million, a price-to-earnings ratio of -0.63 and a beta of 0.56.

Institutional Trading of Chemomab Therapeutics

A hedge fund recently bought a new stake in Chemomab Therapeutics stock. XTX Topco Ltd bought a new stake in shares of Chemomab Therapeutics Ltd. Sponsored ADR (NASDAQ:CMMB) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 19,013 shares of the company’s stock, valued at approximately $31,000. XTX Topco Ltd owned 0.31% of Chemomab Therapeutics at the end of the most recent reporting period. 46.05% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

CMMB has been the subject of several research analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of Chemomab Therapeutics in a report on Monday, December 29th. Zacks Research lowered shares of Chemomab Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Tuesday, November 18th. One equities research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Chemomab Therapeutics currently has an average rating of “Hold” and a consensus target price of $25.00.

About Chemomab Therapeutics

Chemomab Therapeutics (NASDAQ:CMMB) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of next-generation antibody therapies. The company leverages a proprietary antibody engineering platform to generate novel bi- and multi-specific antibodies with applications in oncology, infectious diseases and inflammatory disorders. By combining cutting-edge discovery tools with translational research, Chemomab aims to advance promising candidates from early proof-of-concept through clinical development.

Among its pipeline programs, Chemomab is advancing antibody candidates designed to target key tumor antigens and pathogen-specific epitopes.